Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Non-Insulin Therapies For Diabetes Market Expected To Grow In Terms Of Size?

The market for non-insulin diabetes treatments has seen robust growth in recent years. The market, which was valued at $19.98 billion in 2024, is projected to increase to $21.21 billion in 2025, with a compound annual growth rate (CAGR) of 6.1%. The impressive growth during the historical period can be attributed to factors such as the rising prevalence of diabetes, heightened awareness about diabetes management, increased healthcare spending, lifestyle changes that result in higher incidence rates, a spike in diagnoses, more government initiatives geared towards diabetes care, and an escalation in investment in pharmaceutical R&D.

Expectations are high for robust expansion in the non-insulin therapies for diabetes market over the upcoming years. The market is forecasted to rise to $26.98 billion by 2029, with a compound annual growth rate (CAGR) of 6.2%. Factors contributing to the anticipated growth for this period include an increase in diabetes cases, heightened awareness around diabetes management, the popularity of combined therapies, a growing aging population, higher levels of healthcare spending, the broadening scope of telemedicine, and a preference for oral medications. Future trends to watch for in this period include progress in oral and injectable drugs, improvements in systems for drug delivery, enhancements in oral peptide delivery, the embracing of telemedicine and digital health solutions, and progress in combined therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp

Which Key Factors Are Fueling Growth In The Non-Insulin Therapies For Diabetes Market?

The escalating prevalence of diabetes is expected to spur non-insulin therapies for the diabetes market’s growth. Characterized by elevated blood glucose levels, diabetes is a chronic health condition that arises when the body fails to produce or correctly utilize insulin. The rising number of diabetes instances is attributed to factors like sedentary lifestyles, unhealthy eating habits, genetic susceptibility, aging demographics, obesity, ethnicity, lack of awareness, restricted healthcare access, and environmental influences. Non-insulin diabetes therapies aid in treating the condition by increasing insulin sensitivity, lowering liver glucose production, enhancing glucose uptake in muscle cells, and benefiting overall glycemic control. For example, in April 2023, The British Diabetic Association, a UK-based diabetes charity, published a report stating that 4.3 million people in the UK were diagnosed with diabetes. There was an increase of 148,951 cases in 2021-22 compared to 2020-21, according to the registration data. Moreover, over 2.4 million individuals in the UK are at a high risk of contracting type 2 diabetes. Consequently, the rising prevalence of diabetes is fueling the expansion of non-insulin therapies for the diabetes market.

How Is The Non-Insulin Therapies For Diabetes Market Categorized Across Applications And Types?

The non-insulin therapies for diabetesmarket covered in this report is segmented –

1) By Drug Class: Biguanides; Sulfonylureas; Thiazolidinedione’s; Alpha-Glucosidase Inhibitors; Dipeptidyl peptidase-4 (DPP-4) Inhibitors; Glucagon-like peptide-1 (GLP-1) Analogs; Sodium-glucose co-transporter-2 (SGLT2) Inhibitors

2) By Route Of Administration: Oral; Intramuscular

3) By Distribution Channel: Retail Pharmacy; Hospital Pharmacy; Online Pharmacy

4) By Application: Monitoring; Diagnosis; Treatment; Other Applications

Subsegments:

1) By Biguanides: Metformin; Combination Of Metformin With Other Drugs

2) By Sulfonylureas: Glimepiride; Glipizide; Glyburide

3) By Thiazolidinediones: Pioglitazone; Rosiglitazone

4) By Alpha-Glucosidase Inhibitors: Acarbose; Miglitol

5) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin

6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide; Liraglutide; Dulaglutide; Semaglutide

7) By Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Canagliflozin; Dapagliflozin; Empagliflozin

How Are Market Trends Influencing Competition In The Non-Insulin Therapies For Diabetes Market?

Leading entities in the market for non-insulin diabetes therapies are advancing personalized diabetes management systems to improve patient outcomes by utilizing real-time monitoring, data analysis, and bespoke treatment plans. Such a system personalizes treatment and supervision based on the unique requirements of every patient, using real-time data and analytics for better patient care and results. For example, Eli Lilly and Company, a pharmaceutical firm based in the USA, introduced the Tempo personalized diabetes management platform in November 2022. The platform comprises three main sections: the Tempo Smart Button, the TempoSmart app, and the preloaded insulin pen, known as the Tempo Pen. All these components work together to deliver individualized advice to adults with diabetes. Lilly insulins help the tech platform in guiding adults diagnosed with type 1 or type 2 diabetes and their healthcare providers in making well-informed, data-based treatment choices.

Which Firms Are Making The Biggest Impact In The Non-Insulin Therapies For Diabetes Market?

Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report

Which Region Holds The Greatest Opportunity For Non-Insulin Therapies For Diabetes Market Expansion?

North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=16494&type=smp

Browse Through More Reports Similar to the Global Non-Insulin Therapies For Diabetes Market 2025, By The Business Research Company

Insulin Patch Pumps Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulin-patch-pumps-global-market-report

Insulin Biosimilars Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulin-biosimilars-global-market-report

Non Injectable Insulin Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model